Speaker(s): 

David Ermak, MD, Physician, Geisinger - has nothing to disclose.

Mentor:  

Anthony Noto MD, Physician, Geisinger - has nothing to disclose.

Learning Objectives:

• Examine the evidence for argatroban’s use in AIS
• Discuss utility and practicality of Argatroban for patients at Geisinger

Follow up questions:

1. How does argatroban differ from other current AIS treatments?
2. Is Argatroban safe for use in stroke patients?
3. What are the barriers to implementation of such treatment at Geisinger?

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Anthony Noto, MD, David Ermak, DO, Lisa Wasko, BSN, RN, SCRN have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None